Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease

Br J Dermatol. 2017 Nov;177(5):e206-e208. doi: 10.1111/bjd.15593. Epub 2017 Oct 22.

Authors

C Hurabielle¹, F Sicre de Fontbrune², H Moins-Teisserenc^{3

4}, M Robin², M Jachiet¹, T Coman², N Dhedin², C Cassius¹, F Chasset¹, A de Masson¹, D Michonneau², M Bagot^{1

4}, A Bergeron^{4

5}, G Socié^{2

4}, R Peffault de Latour^{2

4}, J-D Bouaziz^{1

4}

Affiliations

¹ Service de Dermatologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.
² Service d'Hématologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.
³ Service d'Immunobiologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.
⁴ Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.
⁵ Service de Pneumologie, AP-HP, Hôpital Saint-Louis, Paris, 75010, France.

PMID: 28422274
DOI: 10.1111/bjd.15593

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Chronic Disease
Dermatologic Agents / therapeutic use*
Female
Graft vs Host Disease / drug therapy*
Humans
Male
Middle Aged
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines
Retrospective Studies
Scleroderma, Localized / drug therapy*
Treatment Outcome
Young Adult

Substances

Dermatologic Agents
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib